Read More

Summit Therapeutics’ Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck’s Multi-Billion Keytruda In China Study

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly improved progression-free survival in NSCLC patients compared to Keytruda.

MRK

Read More

What’s Going On With Sports Betting And Gambling Company Flutter Entertainment On Friday?

Flutter Entertainment Plc (NYSE: FLUT) announced CFO's departure & replacement by Rob Coldrake. Shift to US market faces challenges, but reports strong growth in revenue, EBITDA & EPS. FLUT stock down 4% in last 12 months. Investors can access industry through ESPO & HERO ETFs. FLUT down 2.47% premarket at $183.25.

ESPO